
Halifax, Nova Scotia, 26 August 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received approval from Health Canada for its Reveal®

Halifax, Nova Scotia, July 16, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started

Halifax, Nova Scotia, 17th of April, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and Lovell® Government Services announced today that they have partnered to serve

Halifax, Nova Scotia, 27th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its partnership with MediGroup, a leader in the US health

Halifax, Nova Scotia, 25th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian

Halifax, Nova Scotia, 21st of January, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health

Halifax, Nova Scotia – January 14, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today the approval from Health Canada

Halifax, Nova Scotia, 9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing authorization (ITA) from Health Canada to
Contacts Investor Relations
For more information about MedMira or inquiries related to Investor Relations, please contact us. Our Investor relations team will get back to you immediately.
Corporate Headquarters
155 Chain Lake Drive, Suite 1
Halifax, Nova Scotia B3S 1B3
Canada
Phone: 902 450 1588
T/F. 877 633 6372
E-Mail: ir@medmira.com